Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: selumetinib, trametinib dimethyl sulfoxide, selumetinib sulfate +15 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 1 stopped | 0.20 |
| literature PubMed | 1 Parkinson's papers of 235 | 0.91 |
| pathways Reactome | 14 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 12975
Sealed predictions
- MAP2K2 in dopamine neurons, braak-0.52 (p 0.155) → +0.11 (p 0.775)receipt 12983
Swarm cases
receipt 12983: MAP2K2 in dopamine neurons, braak
- power
- full sample -0.01 (p 0.969, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.05 (p 0.834, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.14 (p 0.585, n 18). could be the mix.
- skeptic
- leave-one-out range -0.09 to +0.13, sign flips 5; without severely affected donors -0.01 (p 0.969, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.72 (p 8.2e-4, n 18) vs -0.01 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAP2K2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MAP2K2 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.15 p 0.594 (needs p < 1.7e-4)
Receipts
loading the receipts